macular degeneration H35.3
Conditions
Interventions
Group 1: patients only treated with Eylea will be compared to other groups in terms of visual outcomes (best-corrected visual activity) and (retinal thickness-determined) morphological stability (prim
Sponsors
Berner Augenklinik
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Patients suffering from wet AMD requiring intravitreal therapy, either newly diagnosed (treatment-naive) or pretreated with Ranibizumab in case of insufficient response or other reasons.
Exclusion criteria
Exclusion criteria: - any systemic disease potentially worsening under therapy (i.e. recent history of stroke or myocardial infarct) - structural damage to the macula excluding functional gain - any systemic disease interfering with local situation (i.e. Diabetes with advanced diabetic retinopathy)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of anatomical (central retinal thickness) and functional outcomes (best-corrected visual acuity) between the groups at different measurement points (start of therapy, therapy process, end of therapy with old supplement, start of therapy with new supplement, therapy process, end of therapy with new supplement). Central retinal thickness measured in µm was determined by optical coherence tomography (Spectralis TM, Heidelberg Engineering, Heidelberg, Germany), best corrected visus was determined on a logarithmic scale converted to logMAR-valus and standardized ETDRS-measurement. | — |
Secondary
| Measure | Time frame |
|---|---|
| The number of intravitreal injections needed to achieve a stable retinal situation, treatment intervals | — |
Countries
Switzerland
Contacts
Public ContactJustus G. Garweg
Berner Augenklinik
Outcome results
None listed